Edit
Aldagen
http://www.aldagen.com/Last activity: 16.07.2012
Active - Reference to Carpet Cleaning in The Woodlands » Business Directory
Aldagen's proprietary products identify and isolate unique populations of adult stem cells with the potential to revolutionize treatments of cardiovascular disease and degenerative diseases.
Location: United States, North Carolina, Durham
Total raised: $80.65M
Investors 2
| Date | Name | Website |
| - | The Trelys... | trelys.com |
| - | Tall Oaks ... | talloaksca... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.01.2012 | - | $645K | - |
| 05.04.2011 | IPO | $80M | - |
Mentions in press and media 16
| Date | Title | Description |
| 16.07.2012 | Stem cell treatment for ischemia, heart failure raises enough for clinical trials | Its current funding round should last the business into 2014, he said. Juventas’ competitors include everyone from Michigan startup Aastrom Biosciences to the Israeli public company Pluristem Therapeutics. They’re chasing a massive market. ... |
| 16.05.2012 | Two stem cell therapies from Cytomedix to start trials; stroke study expands | Cytomedix’s goal is to ultimately find large pharmaceutical partners to commercialize these treatments. These additional clinical studies don’t represent those kinds of partnerships. Rosendale said there are two facilities that will conduct... |
| 09.02.2012 | CMXI’s Aldagen acquisition is no exit; stem cell payoff is still down the road | Aldagen’s “bright cell” technology isolates stem cells that express high levels of the ALDH enzyme, which have the potential to promote cell and tissue regeneration. The Durham, North Carolina company was formed in 2000 as StemCo Biomedical... |
| 08.02.2012 | Stem cell therapeutics firm Aldagen acquired by Cytomedix in stock deal | “This strategic acquisition of Aldagen provides Cytomedix with a novel, patent-protected cell selection technology that fits well with our existing commercial products and strengthens our long-range growth profile,” Cytomedix CEO Martin Ros... |
| 18.01.2012 | Stem cell therapeutics firm Aldagen expands fundraiser to $645K | Venture capital-backed Aldagen has raised more than $60 million from investors that include the Aurora Funds, Intersouth Partners, Harbert Venture Partners, CNF Investments and Tullis-Dickerson. The company in 2009 filed plans to go public.... |
| 03.06.2011 | N.C. Biotech Center names biotech veteran to head western regional office | The Biotechnology Center is a private, nonprofit corporation supported by the North Carolina General Assembly. The Biotechnology Center, headquartered in Research Triangle Park, has five regional offices that carry out the center’s mission ... |
| 07.04.2011 | Stem cell firm Aldagen cancels $80 million IPO | Stem cell therapy company Aldagen is pulling back on its plans for an initial public offering. The Durham, N.C.-based company revealed in a filing with the Securities & Exchange Commission that it is withdrawing its IPO plans due to mar... |
| 05.04.2011 | Stem cell therapy firm Aldagen withdraws plans for $80M IPO | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| 13.09.2007 | Life sciences briefing: Thursday, Sept. 13, 2007 | Featured companies: Aldagen, LDR, Lyten Endoscopy, MachLabs, Permatox, TeleMedicine Clinic, ThromboVision Spinal-implant maker LDR raises $25M — Austin, Texas-based LDR, a maker of spinal implants, raised $25 million in a third funding roun... |
| - | Stem cell therapeutics firm Aldagen expands fundraiser to $645K | Stem cell technology company Aldagen, which last year withdrew initial public stock offering plans that could have raised up to $80 million to finance R&D and clinical trials, is now raising money in much smaller increments. The Durham,... |
Show more